Pfizer's Gulfstream returns from Paris as German healthcare reform backlash intensifies

Pfizer's Gulfstream G650ER (N5CP) was tracked departing Paris-Le Bourget on June 26 and arriving at Trenton-Mercer after a 6-hour 56-minute crossing. The aircraft had flown the same route in reverse the previous day, suggesting a brief transatlantic turn.

If Pfizer leadership was aboard, the trip would land the same week CEO Albert Bourla warned Germany that proposed healthcare reforms threaten pharmaceutical investment, per a report published June 25 by kpcomaha.org. Bourla's letter to Chancellor Friedrich Merz pushed back against drug price cuts aimed at saving €16.3 billion by 2027, arguing the policy risks driving innovation away from Europe.

The Paris stop fits a pattern: N5CP has visited Le Bourget four times in the past six weeks, including a São Paulo–Paris leg on May 22 and a Mexico City–Paris leg on May 18. Pfizer maintains a significant European presence, and the aircraft's recurring trips to France suggest ongoing regulatory or commercial discussions — now set against a backdrop of pipeline setbacks and a CFO transition announced for August.